Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

gamma-Secretase modulators.

Michael S Wolfe1

  • 1Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. mwolfe@rics.bwh.harvard.edu

Current Alzheimer Research
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The γ-secretase complex: from discovery to a therapeutic target.

RSC chemical biology·2026
Same author

A C. elegans model of familial Alzheimer's disease shows age-dependent synaptic degeneration independent of amyloid β-peptide.

Neurobiology of disease·2026
Same author

A <i>C. elegans</i> model of familial Alzheimer's disease shows age-dependent synaptic degeneration independent of amyloid β-peptide.

bioRxiv : the preprint server for biology·2025
Same author

Presenilin-1 Familial Alzheimer Mutations Impair γ-Secretase Cleavage of APP Through Stabilized Enzyme-Substrate Complex Formation.

Biomolecules·2025
Same author

γ-Secretase-Mediated Endoproteolysis of Neuregulin-1 and E-Cadherin.

Biochemistry·2025
Same author

Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer's Disease.

Biochemistry·2025
Same journal

The Role of Digital Health Technologies in Early Detection and Management of Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Quantifying Short-Term Functional Changes After Lecanemab Treatment in Early Alzheimer's Disease: An Exploratory 3-Month Follow-Up Case Report Using Eye Movement and Gait Analysis.

Current Alzheimer research·2026
Same journal

Corrigendum to: Advancing Alzheimer's Disease Diagnosis Using VGG19 and XGBoost: A Neuroimaging-Based Method.

Current Alzheimer research·2026
Same journal

Corrigendum to: Lithium Chloride Improves Electrophysiological and Memory Deficits in Rats with Streptozotocin-Induced Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Apolipoprotein E Mimetics in Targeted Drug Delivery: Advances and Therapeutic Potential for Neurodegenerative and Cardiovascular Diseases.

Current Alzheimer research·2026
Same journal

Association of Polymorphisms in Genes Involved in Serotonergic Signaling with the Risk of Developing Alzheimer's Disease.

Current Alzheimer research·2026
See all related articles

Gamma-secretase inhibitors offer Alzheimer's disease (AD) therapeutic potential by targeting amyloid beta-peptide (Abeta) production. Selective modulation of gamma-secretase activity is key to avoiding toxicities associated with inhibiting Notch signaling.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Gamma-secretase, an intramembrane-cleaving protease, processes amyloid precursor protein (APP) to generate amyloid beta-peptide (Abeta), a key factor in Alzheimer's disease (AD) pathogenesis.
  • This protease complex, containing presenilin as its catalytic subunit, also cleaves other critical substrates like the Notch receptor, essential for cellular differentiation.
  • Inhibition of gamma-secretase activity can lead to severe toxicities due to its role in Notch signaling, posing a challenge for therapeutic development.

Purpose of the Study:

  • To explore gamma-secretase as a therapeutic target for Alzheimer's disease.
  • To investigate strategies for selective inhibition of Abeta production while preserving Notch signaling.
  • To highlight the potential of allosteric modulators in overcoming the challenges of gamma-secretase inhibition.

Related Experiment Videos

Main Methods:

  • Review of gamma-secretase function and substrate processing.
  • Analysis of the structural components and catalytic mechanism of gamma-secretase.
  • Discussion of allosteric modulation as a therapeutic approach.

Main Results:

  • Gamma-secretase's dual role in APP and Notch processing presents a therapeutic dilemma.
  • Allosteric modulators offer a promising strategy for selective inhibition of gamma-secretase activity.
  • Medicinal chemistry modifications of these modulators are expected to yield viable clinical candidates.

Conclusions:

  • Selective targeting of gamma-secretase for Alzheimer's disease treatment is feasible through allosteric modulation.
  • Developing compounds that inhibit Abeta production without affecting Notch signaling is crucial for therapeutic success.
  • Further research and development of gamma-secretase modulators hold significant promise for Alzheimer's therapeutics.